MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Intraperitoneal Chemotherapy

Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy.

European journal of surgical oncology [Link] Nizri E, Baratti D, Guaglio M, Sinukumar S, Cabras A, Kusamura S, Deraco M Abstract BACKGROUND: Multicystic peritoneal mesothelioma (MCPM) is an extremely rare disease with 40-50% rate of recurrence after surgical debulking. Due to the recurrent nature of the disease, the option of cytoreductive surgery combined with hyperthermic […]

Comments Off on Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy.

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

BMC Cancer 2018 April [Link] Giger-Pabst, Demtröder, Falkenstein, Ouaissi, Götze, Rezniczek, Tempfer Abstract BACKGROUND: Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options. METHODS: We performed a retrospective cohort study of patients with recurrent MM undergoing Pressurized IntraPeritoneal/Thoracal Aerosol Chemotherapy (PIPAC/PITAC) with doxorubicin 1.5 mg/m2 and cisplatin 7.5 mg/m2. […]

Comments Off on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study

European Journal of Surgical Oncology 2018 February [Epub ahead of print] [Link] Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M Abstract BACKGROUND: The differential diagnosis between diffuse malignant peritoneal mesothelioma (DMPM) and other peritoneal surface malignancies (PSM) is still challenging. Serum mesothelin and osteopontin are […]

Comments Off on Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study

Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma

Annals of Surgical Oncology 2018 February [Epub ahead of print] [Link] Alexander HR Jr., Li CY, Kennedy TJ Abstract PURPOSE: Diffuse malignant peritoneal mesothelioma (MPM) is a rare and ultimately fatal cancer that was first described just over a century ago. It is a diffuse malignancy arising from the mesothelial lining of the peritoneum; morbidity […]

Comments Off on Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma

Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)

Journal of Surgical Oncology 2017 November 28 [Epub ahead of print] [Link] Fisher SB, Rafeeq S, Hess K, Grotz TE, Mansfield P, Royal R, Badgwell B, Fleming J, Fournier K, Mann GN Abstract BACKGROUND: Elevated BNP is associated with adverse cardiac outcomes after noncardiac surgery. We assessed BNP values as markers of perioperative fluid status […]

Comments Off on Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)

Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review

Journal of Gastrointestinal Oncology 2017 October [Link] García-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ Abstract Peritoneal mesothelioma (PM) is an uncommon but a serious, and often, fatal primary peritoneal tumour, with increasing incidence worldwide. Conventional systemic chemotherapy, generally based on experience with pleural mesothelioma, usually has disappointing results considering PM […]

Comments Off on Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review

Abdominal Wall Morbidity Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Scandinavian Journal of Surgery 2017 March [Epub ahead of print] [Link] Struller F, Koenigsrainer I, Horvath P, Koenigsrainer A, Beckert S Abstract BACKGROUND: Incisional hernia formation has been reported as high as 20% within 1 year following midline laparotomy. Since hyperthermic intraperitoneal chemotherapy is likely to impair wound healing, we sought to investigate the incidence […]

Comments Off on Abdominal Wall Morbidity Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

European Journal of Surgical Oncology 2017 Janury 29 [Epub ahead of print] [Link] Sugarbaker PH, Chang D Abstract PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases […]

Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Mentored experience of establishing a national peritoneal malignancy programme – Experience of first 50 operative cases

European Journal of Surgical Oncology 2016 November [Epub ahead of print] [Link] Chang KH, Kazanowski M, Staunton O, Cahill RA, Moran BJ, Shields C, Mulsow J Abstract BACKGROUND: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are considered standard of care for pseudomyxoma peritonei (PMP) and selected patients with colorectal peritoneal metastases (CPM) or peritoneal […]

Comments Off on Mentored experience of establishing a national peritoneal malignancy programme – Experience of first 50 operative cases

Trabectedin is active against malignant pleural mesothelioma cell and xenograft models and synergizes with chemotherapy and bcl-2 inhibition in vitro

Molecular Cancer Therapeutics 2016 August 10 [Epub ahead of print] [Link] Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Doeme B, Grusch M, Hegedues B, Berger W Abstract Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to […]

Comments Off on Trabectedin is active against malignant pleural mesothelioma cell and xenograft models and synergizes with chemotherapy and bcl-2 inhibition in vitro